biote (NASDAQ:BTMD) Issues Quarterly Earnings Results

biote (NASDAQ:BTMD) issued its earnings results on Wednesday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports. biote had a negative return on equity of 22.33% and a net margin of 3.19%. The company had revenue of $43.33 million for the quarter, compared to the consensus estimate of $44.01 million.

Here are the key takeaways from biote’s conference call:

• Procedure revenue remained under pressure: Q3 revenue fell 9.6% to $43.3 million, while procedure revenue declined 15.1% to $28.9 million, with the January recall contributing to slower-than-expected recovery. Management cited modest improvement in average daily procedure volume but said sustained growth still requires work.
• Profitability declined sharply year over year: Net income was $0.6 million versus $9.2 million a year earlier, and diluted EPS was $0.01 versus $0.22. Gross margin fell to 67.7% from 71.8%, partly due to reliance on lower-margin third-party pellets.
• Gross margin showed sequential recovery: It improved 231 basis points from Q2 as pellet sourcing shifted back toward Biote’s internally manufactured supply. Asteria Health was back to pre-recall levels and expected to supply more than half of shipped pellets.
• Supplements continued to grow: Revenue rose 7.3% to $12.0 million, primarily driven by the e-commerce channel.
• Full-year 2026 guidance was maintained at revenue above $175 million and Adjusted EBITDA above $25 million. Management pointed to encouraging procedure trends, while emphasizing that improved sales productivity, clinic retention, and practitioner engagement remain necessary to restore growth.

biote Stock Up 9.8%

NASDAQ BTMD traded up $0.11 during trading hours on Wednesday, hitting $1.23. The company’s stock had a trading volume of 105,562 shares, compared to its average volume of 106,590. The stock has a fifty day moving average of $1.27 and a 200 day moving average of $1.81. biote has a twelve month low of $1.00 and a twelve month high of $2.98. The firm has a market capitalization of $44.19 million, a P/E ratio of 3.29 and a beta of 1.73.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. TD Cowen dropped their target price on shares of biote from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Weiss Ratings cut shares of biote from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 13th. Finally, B. Riley Financial dropped their price objective on biote from $2.00 to $1.50 and set a “neutral” rating for the company in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $2.50.

Insider Buying and Selling at biote

In related news, Chairman Marc Beer purchased 115,950 shares of biote stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $177,403.50. Following the transaction, the chairman directly owned 223,744 shares of the company’s stock, valued at approximately $342,328.32. This trade represents a 107.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 32.40% of the stock is currently owned by company insiders.

biote Company Profile

Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.

The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.